Herpes Zoster Pain
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with HZ-related pain presenting at the study site between February 1, 2024, and December 30, 2025; 2.Aged 18–80 years, any gender; 3.Numeric Rating Scale (NRS) pain score = 4; 4.Persistent neuralgia following 7 days of antiviral therapy, with pain duration not exceeding 1 month; 5.Cooperate to complete the treatment and adhere to the medication regimen as prescribed. 6.No analgesic use within 3 days prior to enrollment; 7.Willing and able to adhere to the treatment protocol; Capable of understanding study procedures and providing informed consent
Exclusion criteria
Exclusion criteria: (1) Patients with critical conditions (hemodynamic instability, respiratory failure, or respiratory depression requiring intubation); (2) Patients with atypical herpes zoster (such as disseminated herpes zoster, or skin lesions involving the head, face, neck, shoulders, or lower back); (3) Patients with abnormal coagulation function; (4) Patients with cardiovascular and cerebrovascular diseases, kidney, liver, or other organ diseases, or those with mental disorders; (5) Patients with hematologic diseases or poorly controlled blood glucose; (6) Women who are pregnant or breastfeeding; (7) Patients allergic to the treatment drugs; (8) Patients with significant cognitive impairment affecting their understanding of or compliance with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numerical Rating Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| The State Anxiety Inventory (S-AI);IL-6, IL-8, and TNF-a;The frequency of analgesic use and the occurrence of adverse reactions during the treatment process.;the incidence of Postherpetic neuralgia; | — |
Countries
China
Contacts
The Third Affiliated Hospital of Zhejiang Chinese Medical University